Los Angeles, CA -- (SBWire) -- 05/06/2019 --Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.

Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.

Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1086562/global-amifostine-market

The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.

Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.

The global Amifostine market was 48 million US$ in 2018 and is expected to 57 million US$ by the end of 2025, growing at a CAGR of 2.2% between 2019 and 2025.

This report studies the Amifostine market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Amifostine in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Clinigen Group

Sun Pharmaceutical

Taj Pharmaceuticals

Merro Pharmaceutical

Luye Pharma

Mingren Pharma

By the product type, the market is primarily split into

400mg/Dose

500mg/Dose

By the end users/application, this report covers the following segments

Head and Neck Cancer Adjuvant Therapy

Others

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/settlement/pre/1cffb20b3345b9ef4af97f38b63e4cd0,0,1,Global%20Amifostine%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.